“Plaintiffs have come forth with a vast body of evidence, substantially laid out below, amply amounting to reasonable evidence of a causal association between use of Gardasil and autoimmune ...

Merck’s MRK second-largest product is Gardasil, which is a vaccine for the prevention of certain cancers caused by human papillomavirus (HPV). Though the vaccine’s sales rose consistently till ...

Merck has emerged victorious in consolidated litigation over the safety of Gardasil, knocking out hundreds of HPV vaccine lawsuits in the process.

Federal judge rules in favor of Merck over Gardasil lawsuits, citing lack of evidence linking the HPV vaccine to serious conditions. Read more here.

A federal judge ruled in Merck & Co.’s favor in a safety lawsuit over its Gardasil vaccine, allowing the drugmaker to sidestep more than 200 cases claiming the company concealed safety risks.

(Reuters) -A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus ...

U.S. District Judge Kenneth Bell, who is overseeing the Gardasil multidistrict litigation in the Western District of North Carolina, sided with Merck on its implied preemption defense, granting ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year forecast and ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling ...

Merck's Gardasil sales fell short of expectations in the fourth quarter, and the company pulled its long-term target of $11 billion in Gardasil sales by 2030 in light of the decision to stop shipments ...